Morfex (Flurazepam Hydrochloride)

Flurazepam binds to the benzodiazepine site on the GABA‑A receptor, enhancing the inhibitory effect of the neurotransmitter GABA. This increased chloride influx hyperpolarizes neurons, producing a calming effect that facilitates sleep initiation and maintenance.

The appropriate dose of Morfex is determined by the prescribing clinician based on the patient’s age, medical condition, and response to therapy. Dosage adjustments may be needed for renal or hepatic impairment, and the medication should be taken exactly as directed.

Safety of flurazepam in pregnancy or while breastfeeding has not been definitively established. Women who are pregnant, planning to become pregnant, or nursing should discuss potential risks and benefits with their healthcare provider before using Morfex.

To request Morfex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Morfex (flurazepam) belongs to the benzodiazepine class, offering rapid onset of sleep but with a risk of dependence and next‑day sedation. Non‑benzodiazepine hypnotics (e.g., zolpidem) have a shorter half‑life and lower dependence potential, while melatonin receptor agonists act via a different pathway and are generally considered safer for long‑term use.

Morfex should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain potency and stability throughout its shelf life.

Morfex is taken orally, usually once nightly before bedtime. The tablet should be swallowed whole with a glass of water and not chewed or crushed. Patients should follow the prescribing clinician’s instructions regarding timing and any required dose adjustments.

Serious risks include respiratory depression, severe allergic reactions, paradoxical agitation, depression or suicidal thoughts, and the potential for physical dependence and withdrawal symptoms after prolonged use. Immediate medical attention is required if any of these events occur.

Morfex is contraindicated in individuals with known hypersensitivity to flurazepam or other benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in patients who are currently abusing alcohol or other CNS depressants. It should also be used with extreme caution in the elderly and in those with significant hepatic or renal impairment.